Intensity of Cyclophosphamide-Based Bridging Therapy Before Chimeric Antigen Receptor T Cell Therapy in Myeloma-Reference-Cited by-同舟云学术

Intensity of Cyclophosphamide-Based Bridging Therapy Before Chimeric Antigen Receptor T Cell Therapy in Myeloma

Published:2023-08 Issue:8 Volume:29 Page:504.e1-504.e7
ISSN:2666-6367
Container-title:Transplantation and Cellular Therapy
language:en
Short-container-title:Transplantation and Cellular Therapy

Author:

Zafar Aneeqa^ORCID,Huang Chiung-Yu,Lo Mimi,Arora Shagun,Chung Alfred^ORCID,Wong Sandy W.,Wolf Jeffrey,Martin Thomas G.^ORCID,Shah Nina,Banerjee Rahul^ORCID

Funder

University of California

Publisher

Elsevier BV

Subject

Transplantation,Cell Biology,Hematology,Molecular Medicine,Immunology and Allergy

Reference33 articles.

1. Idecabtagene vicleucel in relapsed and refractory multiple myeloma;Munshi;N Engl J Med,2021

2. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study;Berdeja;Lancet,2021

3. A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma;Wang;Blood,2021

4. GPRC5D-targeted CAR T cells for myeloma;Mailankody;N Engl J Med,2022

5. Results from the first phase 1 clinical study of the B-cell maturation antigen (BCMA) Nex T chimeric antigen receptor (CAR) T cell therapy CC-98633/BMS-986354 in patients (pts) with relapsed/refractory multiple myeloma (RRMM);Costa;Blood,2022

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The emerging role of melflufen and peptide-conjugates in multiple myeloma;Current Opinion in Oncology;2024-08-22

2. Obstacles to global implementation of CAR T cell therapy in myeloma and lymphoma;Frontiers in Oncology;2024-07-19

3. Fast and furious: Changing gears on the road to cure with chimeric antigen receptor T cells in multiple myeloma;Seminars in Hematology;2024-07

4. Overcoming the challenges of primary resistance and relapse after CAR-T cell therapy;Expert Review of Clinical Immunology;2024-05-14

5. Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium;Blood Cancer Journal;2024-04-12